The United Bio-technology (hengqin) Co., Ltd.
Clinical trials sponsored by The United Bio-technology (hengqin) Co., Ltd., explained in plain language.
-
New weekly shot aims to protect kidneys in obese patients
Disease control Recruiting nowThis study tests a weekly injection called UBT251 in 180 overweight or obese adults with chronic kidney disease. The goal is to see if it can reduce protein in the urine (a sign of kidney damage) and help with weight control. Participants will receive either the drug or a placebo…
Phase: PHASE2 • Sponsor: The United Bio-Technology (Hengqin) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New weekly shot aims to reverse fatty liver damage
Disease control Recruiting nowThis study tests a new drug called UBT251, given as a weekly injection, for people with MASH (a serious fatty liver disease with scarring). 156 adults will be randomly assigned to receive one of three doses of UBT251 or a placebo for 48 weeks. The main goal is to see if the drug …
Phase: PHASE2 • Sponsor: The United Bio-Technology (Hengqin) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC